Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Proteonomix Settles Litigation PR Newswire PARAMUS, N.J., April 1, 2013 PARAMUS, N.J., April 1, 2013 /PRNewswire/ -- Proteonomix, Inc. (OTC:...
Proteonomix Announces Extension Of Deadline /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prn...
Proteonomix To Require Physical Exchange Of Certificates /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:b...
Proteonomix Announces Restructuring /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a {...
Proteonomix Updates Status Of UMK-121 Testing /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.p...
Proteonomix, Inc. Announces Screening of Patients with End Stage Liver Disease in its Clinical Study of UMK-121 /* Style Definitions...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Proteonomix, Inc. Announces Finalizing ECRF for Its Clinical Trial of UMK 121 in Patients with End Stage Liver Disease /* Style Definitions...
Proteonomix, Inc. Announces Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease Has Been Listed on ClinicalTrials.gov /...
SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
Proteonomix, Inc. Announces IRB Approval for Its Clinical Trial of UMK-121 in Patients with End Stage Liver Disease PR Newswire PARAMUS, N.J...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q /A X ...
UNITED STATESSECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A X &nb...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지